Hernández-Hernández David, Padilla-Fernández Bárbara, Castro Romera Milagros, Hess Medler Stephany, Castro-Díaz David
Servicio de Urología, Hospital Universitario de Canarias, Tenerife, Spain.
Departamento de Cirugía, Facultad de Medicina, Universidad de La Laguna, Tenerife, Spain.
Int Neurourol J. 2021 Dec;25(4):319-326. doi: 10.5213/inj.2040364.182. Epub 2021 Jan 27.
The aim of this study was to analyze the long-term outcomes of sacral nerve stimulation (SNS) in both idiopathic and neurogenic pelvic floor disorders in patients treated at a referral center.
This retrospective observational study analyzed the records of 106 patients tested at our department from December 1999 to January 2017. The efficacy variables evaluated were the Global Response Assessment (range, 0%-100%) and, according to the clinical indication, other specific variables such International Consultation on Incontinence QuestionnaireShort Form, number of catheterizations or pads/day, and the numerical pain scale. The safety variables analyzed were complications (pain, migration, infection), reinterventions and explants. Patients' quality of life (QoL) and satisfaction with the procedure were evaluated through telephone interviews.
The clinical indications were overactive bladder (OAB) (n=36), urinary retention (UR) (n=37), bladder pain syndrome/interstitial cystitis (BPS/IC) (n=19), fecal incontinence (FI) (n=8), and double incontinence (DI) (n=6). The implant rates according to the clinical indication were as follows: OAB, 55.6%; UR, 56.8%; BPS/IC, 63.15%; FI, 87.5%; and DI, 66.7%. Clinical and/or statistically significant improvements in all efficacy variables were observed. Loss of therapeutic effect at 75 months of follow-up was observed in 34% of patients. Device-related pain appeared in 25 patients (39%); in 20 patients, it was resolved by reprogramming and 5 patients required device removal. An overall improvement in QoL and high levels of satisfaction with the procedure were observed. More than 90% of patients would recommend SNS to a friend or relative.
SNS is a minimally invasive procedure that offers a real alternative to patients with refractory pelvic floor dysfunction. Its safety profile is very favorable and it provides a long-lasting improvement in symptoms and QoL.
本研究旨在分析在一家转诊中心接受治疗的特发性和神经源性盆底功能障碍患者骶神经刺激(SNS)的长期疗效。
这项回顾性观察性研究分析了1999年12月至2017年1月在我科接受测试的106例患者的记录。评估的疗效变量包括总体反应评估(范围为0%-100%),并根据临床指征评估其他特定变量,如国际尿失禁咨询问卷简表、每日导尿次数或使用尿垫数以及数字疼痛量表。分析的安全变量包括并发症(疼痛、移位、感染)、再次干预和取出装置。通过电话访谈评估患者的生活质量(QoL)和对该手术的满意度。
临床指征包括膀胱过度活动症(OAB)(n = 36)、尿潴留(UR)(n = 37)、膀胱疼痛综合征/间质性膀胱炎(BPS/IC)(n = 19)、大便失禁(FI)(n = 8)和混合性失禁(DI)(n = 6)。根据临床指征的植入率如下:OAB为55.6%;UR为56.8%;BPS/IC为63.15%;FI为87.5%;DI为66.7%。观察到所有疗效变量均有临床和/或统计学上的显著改善。在随访75个月时,34%的患者出现治疗效果丧失。25例患者(39%)出现与装置相关的疼痛;其中20例通过重新编程解决,5例需要取出装置。观察到患者的生活质量总体改善,对该手术的满意度较高。超过90%的患者会向朋友或亲属推荐SNS。
SNS是一种微创手术,为难治性盆底功能障碍患者提供了一种切实可行的选择。其安全性非常良好,能长期改善症状和生活质量。